MITSUI-CHEMICALS
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Mitsui Chemicals Europe GmbH (Düsseldorf, Germany; President: HIRAIWA Takeshi) will exhibit at K2022 – the World’s No.1 Trade Fair for Plastics and Rubber as the Mitsui Chemicals Group.
The event is scheduled to be held from October 19–26, 2022 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005348/en/
Mitsui Chemicals Group booth (Graphic: Business Wire)
At the trade fair, under the slogan “Feel Good Chemistry for a sustainable world”, the Mitsui Chemicals Group will present innovative materials and solutions that contribute to the circular economy, and a carbon neutral and sustainable society. In addition, technical presentations will be held on October 20th and 24th.
Come and meet us at our booth at K 2022 (hall 7a, booth D18).
- Overview of Mitsui Chemicals Group‘s Exhibition
Exhibition period: |
October 19 (Wed) – October 26 (Wed), 2022 |
Venue: |
Düsseldorf Fairgrounds / Düsseldorf, Germany |
Booth location: |
7a / D18 |
- Exhibition items of Materials and information
Products/Solutions |
Theme |
Arlen™ |
A modified polyamide 6T, heat & hydrolysis resistance for metal replacements and EV components |
Aurum™ |
(TPI), a super engineering plastic for high performance applications at extreme temperatures |
Arcus™ |
Solution service for polymer robot parts including material design/selection and production. |
Exfola™ |
Sealant film for packaging with good oil and water repellency |
Econykol™ |
Biomass based polyols for polyurethanes that contributes to reduce greenhouse gas emissions |
Recycle solutions
|
RePLAYERTM – Renewable plastic layer system - Mono-material packaging solutions Paper packaging solutions |
TAFNEX™ |
Composite material based on polypropylene and carbon fibre for structural and aesthetic applications |
TPXTM |
Polymethylpentene (PMP), a polyolefin based polymer with extremely low density, high melting point, releasability and steam resistance for autoclavable medical and laboratory equipment |
Advanced Module Concept |
Advanced module concept for back-door and slide-door |
Eco-bench |
MMP (Mold Master Plate) - sandwich molding (Recycling) |
- Technical presentations
- October 20, 11:00 o’clock
Theme: "AURUMTM thermoplastic polyimide (TPI)
An innovative solution for the demanding application requirements by maintaining excellent mechanical performance at extreme temperatures"
Presenter: Samer Ziadeh
Technical Expert, Product Support Team, R&D Division
- October 24, 14:00 o’clock
Theme: "Decorative design options with thermoplastic composites based on carbon fiber and polypropylene"
Presenter: Dr. Christos Karatzias
Senior Manager, New Business Development Team, R&D Division
Please visit our dedicated website for more details.
https://eu.mitsuichemicals.com/special/k2022/
About Mitsui Chemicals (Tokyo: 4183, ISIN: JP3888300005)
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life & Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by "Creating New Customer Value through Innovation".
More information can be found at https://www.mitsuichem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom